Dublin, Feb. 10, 2021 (GLOBE NEWSWIRE) -- The "Erythropoietin (EPO) Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.
This report provides strategists, marketers and senior management with the critical information they need to assess the global erythropoietin (epo) market.
This report focuses on erythropoietin (epo) market which is experiencing strong growth. The report gives a guide to the erythropoietin (epo) market which will be shaping and changing our lives over the next ten years and beyond, including the markets response to the challenge of the global pandemic.
The global erythropoietin (EPO) market is expected to decline from $1.01 billion in 2019 to $0.95 billion in 2020 at a compound annual growth rate (CAGR) of -6.27%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disrupted, impacting the market negatively. The market is then expected to recover and reach $2.27 billion in 2023 at a CAGR of 33.9%.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
- Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market research findings.
- Benchmark performance against key competitors.
- Utilize the relationships between key data sets for superior strategizing.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Description:
Where is the largest and fastest growing market for the erythropoietin (epo)? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Erythropoietin (EPO) market global report answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography. It places the market within the context of the wider erythropoietin (epo) market, and compares it with other markets.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, the influence of the COVID-19 virus and forecasting its growth.
- Market segmentations break down market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
- The erythropoietin (epo) market section of the report gives context. It compares the erythropoietin (epo) market with other segments of the erythropoietin (epo) market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, erythropoietin (epo) indicators comparison.
The erythropoietin (EPO) market consists of sales of erythropoietin drugs by entities (organizations, sole traders, and partnerships) that manufacture erythropoietin biosimilars. Erythropoietin (EPO) is a hormone produced by kidneys and plays a vital role in the production of red blood cells, which carry oxygen from the lungs to the rest of the body. Lack of sufficient erythropoietin results in low red blood cells, which may lead to anaemia. The erythropoietin (EPO) drugs are used for treatment for anaemia, kidney disorders, cancer, and other conditions.
In August 2018, STADA Arzneimittel AG, a Germany-based pharmaceutical company, acquired majority stakes (51.34%) in Bioceuticals Arzneimittel AG for an undisclosed amount. The acquisition is expected to expand STADA Arzneimittel AG's presence in the biosimilar sector. Bioceuticals Arzneimittel AG licenses marketing rights to epoetin zeta and epoetin biosimilar to STADA Arzneimittel AG. Bioceuticals Arzneimittel AG is a Germany-based company engaged in manufacturing and marketing active pharmaceutical ingredients including erythropoietin biosimilars.
The erythropoietin market covered in this report is segmented by product into epoetin-alfa; epoetin-beta; darbepoetin-alfa; others and by application into cancer; hematology; renal diseases; neurology; others.
Stringent regulations imposed on the production and sales of erythropoietin drugs are predicted to hinder the growth of the erythropoietin market over the forecast period. For instance, in European Community (EC), technologically advanced medicinal products manufactured using a biotechnological process such as recombinant DNA technology should comply with marketing authorization (MA) under provisions of Regulation (EC) No. 726/04 issued by EC. The regulatory policy for biosimilars is complex and in Europe is mainly governed by guidelines issued by the European Medicines Agency (EMEA). In addition to this, recombinant human erythropoietin (rHuEPO) must fulfill additional product-class specific guidelines apart from regulations on quality, clinical, and non-clinical issues developed by the EMEA.
The rising incidence of chronic kidney diseases is anticipated to propel the demand for the erythropoietin market over the approaching years. According to the Brazilian Journal of Nephrology's statistics published in February 2019, kidney disease is a global public healthcare problem affecting over 750 million people across the globe. In addition to this, according to the Centers for Disease Control and Prevention's report published on chronic kidney disease in the United States, in 2019, 15% of the adults in the USA, or 37 million people are estimated to have chronic kidney disease (CKD). CKD is more common in people aged 65 or older (38%) than in people aged 45-64 years (13%) and 18-44 years (7%). Chronic kidney diseases lead to an anaemic condition which in turn increases the demand for erythropoietin to curb the condition, thereby driving the revenues for the market.
Key Topics Covered:
1. Executive Summary
2. Erythropoietin (EPO) Market Characteristics
3. Erythropoietin (EPO) Market Size and Growth
3.1. Global Erythropoietin (EPO) Historic Market, 2015 - 2019, $ Billion
3.1.1. Drivers of the Market
3.1.2. Restraints on the Market
3.2. Global Erythropoietin (EPO) Forecast Market, 2019 - 2023F, 2025F, 2030F, $ Billion
3.2.1. Drivers of the Market
3.2.2. Restraints on the Market
4. Erythropoietin (EPO) Market Segmentation
4.1. Global Erythropoietin (EPO) Market, Segmentation by Product
4.2. Global Erythropoietin (EPO) Market, Segmentation by Application
5. Erythropoietin (EPO) Market Regional and Country Analysis
5.1. Global Erythropoietin (EPO) Market, Split by Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
5.2. Global Erythropoietin (EPO) Market, Split by Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
6. Asia-Pacific Erythropoietin (EPO) Market
7. China Erythropoietin (EPO) Market
8. India Erythropoietin (EPO) Market
9. Japan Erythropoietin (EPO) Market
10. Australia Erythropoietin (EPO) Market
11. Indonesia Erythropoietin (EPO) Market
12. South Korea Erythropoietin (EPO) Market
13. Western Europe Erythropoietin (EPO) Market
14. UK Erythropoietin (EPO) Market
15. Germany Erythropoietin (EPO) Market
16. France Erythropoietin (EPO) Market
17. Eastern Europe Erythropoietin (EPO) Market
18. Russia Erythropoietin (EPO) Market
19. North America Erythropoietin (EPO) Market
20. USA Erythropoietin (EPO) Market
21. South America Erythropoietin (EPO) Market
22. Brazil Erythropoietin (EPO) Market
23. Middle East Erythropoietin (EPO) Market
24. Africa Erythropoietin (EPO) Market
25. Erythropoietin (EPO) Market Competitive Landscape and Company Profiles
25.1. Erythropoietin (EPO) Market Competitive Landscape
25.2. Erythropoietin (EPO) Market Company Profiles
25.2.1. Amgen Inc.
25.2.1.1. Overview
25.2.1.2. Products and Services
25.2.1.3. Strategy
25.2.1.4. Financial Performance
25.2.2. Johnson & Johnson
25.2.2.1. Overview
25.2.2.2. Products and Services
25.2.2.3. Strategy
25.2.2.4. Financial Performance
25.2.3. Roche Group
25.2.3.1. Overview
25.2.3.2. Products and Services
25.2.3.3. Strategy
25.2.3.4. Financial Performance
25.2.4. Pfizer Inc.
25.2.4.1. Overview
25.2.4.2. Products and Services
25.2.4.3. Strategy
25.2.4.4. Financial Performance
25.2.5. Novartis
25.2.5.1. Overview
25.2.5.2. Products and Services
25.2.5.3. Strategy
25.2.5.4. Financial Performance
26. Key Mergers and Acquisitions in the Erythropoietin (EPO) Market
27. Erythropoietin (EPO) Market Trends and Strategies
28. Erythropoietin (EPO) Market Future Outlook and Potential Analysis
29. Appendix
29.1. Abbreviations
29.2. Currencies
29.3. Research Inquiries
29.4. About the Publisher
29.5. Copyright and Disclaimer
For more information about this report visit https://www.researchandmarkets.com/r/2id815